Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04000555 · ClinicalTrials.gov registry record · Phase 4
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
A Phase 4 study, sponsored by University of South Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT04000555: Clinical Trial Phase 4 study, sponsored by University of South Florida.
NCT04000555 is a Phase 4 study that was terminated before completion, run by University of South Florida. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04000555, a Phase 4 study, was terminated before completion, sponsored by University of South Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.
Primary Outcome
Diagnosis of Clostridium Difficile infection to assess recurrence rates Participants will be called at the completion of systemic antibiotics and 1, 2 and 3 months thereafter to assess for recurrence. If participants were tested for C. difficile at another facility records will be obtained to confirm recurrent infection.
Interventions
- OTHER Placebo
- DRUG Oral Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2022-06-11 |
| Phase | Phase 4 |
Why NCT04000555 stopped before completion
NCT04000555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04000555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04000555 about?
NCT04000555 is a clinical study titled "Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)". The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.
What is the current status of trial NCT04000555?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2019-09-01. Estimated completion is 2022-06-11.
What interventions are being tested in trial NCT04000555?
The interventions under investigation include: Placebo (OTHER), Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT04000555?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04000555's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI